Triplixam Contraindications

Dialysis patients.
Patients with untreated decompensated heart failure.
Severe renal impairment (creatinine clearance below 30 mL/min).
Moderate renal impairment (creatinine clearance below 60 mL/min) for Triplixam doses containing 10mg/2.5mg of perindopril/indapamide combination (i.e., Triplixam 10mg/2.5mg/5mg and 10mg/2.5mg/10mg).
Hypersensitivity to the active substances, to other sulfonamides, to dihydropyridine derivatives, any other ACE-inhibitor or to any of the excipients listed in Description.
History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy (see Precautions).
Hereditary/idiopathic angioedema.
Second and third trimesters of pregnancy (see Precautions and Use in Pregnancy & Lactation).
Hepatic encephalopathy.
Severe hepatic impairment.
Hypokalaemia.
Severe hypotension.
Shock, including cardiogenic shock.
Obstruction of the outflow-tract of the left ventricle (e.g. high grade aortic stenosis).
Haemodynamically unstable heart failure after acute myocardial infarction.
Concomitant use of Triplixam with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60mL/min/1.73m²) (See Interactions and Pharmacology: Pharmacodynamics under Actions).
Concomitant use with sacubitril/valsartan therapy. Triplixam must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see Precautions and Interactions).
Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see Interactions).
Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see Precautions).